Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Statistics

Total Valuation

Marksans Pharma has a market cap or net worth of INR 94.01 billion. The enterprise value is 90.91 billion.

Market Cap	94.01B
Enterprise Value	90.91B

Important Dates

The next confirmed earnings date is Tuesday, May 26, 2026.

Earnings Date	May 26, 2026
Ex-Dividend Date	Aug 1, 2025

Share Statistics

Marksans Pharma has 453.16 million shares outstanding. The number of shares has increased by 0.11% in one year.

Current Share Class	453.16M
Shares Outstanding	453.16M
Shares Change (YoY)	+0.11%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	43.87%
Owned by Institutions (%)	12.14%
Float	214.46M

Valuation Ratios

The trailing PE ratio is 26.10 and the forward PE ratio is 19.96. Marksans Pharma's PEG ratio is 1.10.

PE Ratio	26.10
Forward PE	19.96
PS Ratio	3.35
PB Ratio	3.46
P/TBV Ratio	3.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.10

Enterprise Valuation

EV / Earnings	25.23
EV / Sales	3.24
EV / EBITDA	17.51
EV / EBIT	21.09
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.12
Debt / EBITDA	0.64
Debt / FCF	n/a
Interest Coverage	20.29

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	13.76%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	9.49%
Revenue Per Employee	15.24M
Profits Per Employee	1.96M
Employee Count	1,840
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Marksans Pharma has paid 1.15 billion in taxes.

Income Tax	1.15B
Effective Tax Rate	24.10%

Stock Price Statistics

The stock price has decreased by -9.78% in the last 52 weeks. The beta is 0.98, so Marksans Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	-9.78%
50-Day Moving Average	179.27
200-Day Moving Average	182.01
Relative Strength Index (RSI)	71.71
Average Volume (20 Days)	2,166,370

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Marksans Pharma had revenue of INR 28.03 billion and earned 3.60 billion in profits. Earnings per share was 7.95.

Revenue	28.03B
Gross Profit	15.37B
Operating Income	4.31B
Pretax Income	4.77B
Net Income	3.60B
EBITDA	4.92B
EBIT	4.31B
Earnings Per Share (EPS)	7.95

Balance Sheet

The company has 6.67 billion in cash and 3.32 billion in debt, with a net cash position of 3.35 billion or 7.40 per share.

Cash & Cash Equivalents	6.67B
Total Debt	3.32B
Net Cash	3.35B
Net Cash Per Share	7.40
Equity (Book Value)	27.14B
Book Value Per Share	59.37
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	610.35M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 54.83%, with operating and profit margins of 15.38% and 12.85%.

Gross Margin	54.83%
Operating Margin	15.38%
Pretax Margin	17.00%
Profit Margin	12.85%
EBITDA Margin	17.56%
EBIT Margin	15.38%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.39%.

Dividend Per Share	0.80
Dividend Yield	0.39%
Dividend Growth (YoY)	33.33%
Years of Dividend Growth	3
Payout Ratio	n/a
Buyback Yield	-0.11%
Shareholder Yield	0.28%
Earnings Yield	3.83%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.

Last Split Date	Mar 11, 2008
Split Type	Forward
Split Ratio	10

Scores

Altman Z-Score	n/a
Piotroski F-Score	2